Posted: 12/17/2024 07:30 am
In 2024, Philip Astley-Sparke, the Chief Executive Officer, received a total compensation package valued at $6,018,364 despite no cash bonuses, highlighting the company's focus on equity-based incentives.^1 His package comprised a salary of $649,000, stock awards worth $2,509,486, option awards of $2,548,357, and incentive plan compensation amounting to $311,520. The considerable emphasis on stock and option awards signals an alignment of his interests with shareholder value creation, which, while ambitious, may suggest confidence in the company’s potential for growth.
In the previous year, 2023, another executive, Jean Franchi, was awarded $2,608,123 as her total compensation. Franchi's package, similar in structure, emphasized stock and option awards, with $958,650 and $971,303 respectively, underscoring Replimune's consistent compensation philosophy of linking executive rewards to performance and long-term company success.^2
Interestingly, instances such as the 2021 compensation profile for Sushil Patel, the then Chief Commercial Officer, where total compensation was reported as zero, reflect particular strategic or internal decisions which might involve role changes or leave of absence during that time.^3 Similarly, Philip Astley-Sparke's compensation back in 2020 was lower at $2,155,164, with options being the main driver at $1,541,213, hinting at less aggressive equity incentives compared to 2024.^4
The company’s market performance is critical in understanding these strategic choices. As of the latest data snapshot, Replimune’s stock price stands at $12.48, with a market capitalization of approximately $940,249,440.^5 The stock has witnessed a year-high of $17, showing potential for growth but also volatility, as evidenced by its range and earnings per share (EPS) of -$3.04, resulting in a negative P/E ratio of -4.11.
Overall, Replimune’s executive compensation strategy appears to balance immediate salary with long-term incentives through equity, driving alignment with shareholder interests. This structure posits challenges and opportunities, particularly in the volatile biotech market, as reflected in the company’s financial and stock performance stats.
:
1. SEC Filing - Replimune Group, Inc. 2024. [Link](https://www.sec.gov/Archives/edgar/data/1737953/000110465924081167/0001104659-24-081167-index.htm)
2. SEC Filing - Replimune Group, Inc. 2023. [Link](https://www.sec.gov/Archives/edgar/data/1737953/000110465923084367/0001104659-23-084367-index.htm)
3. SEC Filing - Replimune Group, Inc. 2021. [Link](https://www.sec.gov/Archives/edgar/data/1737953/000110465922082980/0001104659-22-082980-index.htm)
4. SEC Filing - Replimune Group, Inc. 2020. [Link](https://www.sec.gov/Archives/edgar/data/1737953/000110465921094885/0001104659-21-094885-index.htm)
5. Market Snapshot - Replimune Group, Inc. [Data as of Latest Timestamp]
